GRI Bio financials
$2.00−4.76%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — |
| Operating income | -$12.0M | -$8.2M | -$11.4M |
| Net income | -$12.0M | -$10.1M | -$13.0M |
| Net margin | — | — | — |
| Diluted EPS | $-121.80 | $-1545.44 | $-1672.70 |
| EBITDA | -$12.0M | -$8.2M | -$11.4M |
| Operating cash flow | -$10.2M | -$8.6M | -$9.0M |
| Free cash flow | -$10.2M | -$8.6M | -$9.0M |
| Diluted shares | 0.1M | 0.0M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $8.2M | $5.0M | $1.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 |
| Total assets | $8.7M | $5.7M | $3.0M |
| Total liabilities | $2.7M | $1.7M | $2.7M |
| Shareholders' equity | $6.0M | $4.0M | $259.0K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology